These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30576868)

  • 1. t(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression.
    Tang G; Hu S; Wang SA; Xie W; Lin P; Xu J; Toruner G; Zhao M; Gu J; Doty M; Li S; Medeiros LJ; Tang Z
    J Mol Diagn; 2019 Mar; 21(2):343-351. PubMed ID: 30576868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
    Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MECOM rearrangement involving the MYC locus: Two additional patients with the rare translocation, t(3;8)(q26.2;q24), and molecular review.
    Smith SC; Qdaisat TZS; Althof PA; Dave BJ; Sanmann JN
    Leuk Res; 2020 Aug; 95():106387. PubMed ID: 32535247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
    Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
    Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities.
    Ronaghy A; Hu S; Tang Z; Wang W; Tang G; Loghavi S; Li S; Thakral B; Medeiros LJ; Muzzafar T
    Mod Pathol; 2021 Feb; 34(2):300-313. PubMed ID: 33110238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Genomic Profiles of Korean Patients with
    Lee J; Kim SM; Kim S; Yun J; Jeong D; Lee YE; Roh EY; Lee DS
    Ann Lab Med; 2022 Sep; 42(5):590-596. PubMed ID: 35470277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia in blast phase associated with t(3;8)(q26;q24).
    Lin P; Lennon PA; Yin CC; Abruzzo LV
    Cancer Genet Cytogenet; 2009 Sep; 193(2):119-22. PubMed ID: 19665075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
    Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation.
    Gao J; Gurbuxani S; Zak T; Kocherginsky M; Ji P; Wehbe F; Chen Q; Chen YH; Lu X; Jennings L; Frankfurt O; Altman J; Sukhanova M
    Genes Chromosomes Cancer; 2022 Feb; 61(2):71-80. PubMed ID: 34668265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
    Ottema S; Mulet-Lazaro R; Erpelinck-Verschueren C; van Herk S; Havermans M; Arricibita Varea A; Vermeulen M; Beverloo HB; Gröschel S; Haferlach T; Haferlach C; J Wouters B; Bindels E; Smeenk L; Delwel R
    Nat Commun; 2021 Sep; 12(1):5679. PubMed ID: 34584081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular approaches identify a cryptic MECOM rearrangement in a child with a rapidly progressive myeloid neoplasm.
    Capela de Matos RR; Othman MAK; Ferreira GM; Costa ES; Melo JB; Carreira IM; de Souza MT; Lopes BA; Emerenciano M; Land MGP; Liehr T; Ribeiro RC; Silva MLM
    Cancer Genet; 2018 Feb; 221():25-30. PubMed ID: 29405993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient-specific iPSCs.
    Nakamura M; Chonabayashi K; Narita M; Matsumura Y; Nishikawa M; Ochi Y; Nannya Y; Hishizawa M; Inoue D; Delwel R; Ogawa S; Takaori-Kondo A; Yoshida Y
    Br J Haematol; 2024 Oct; 205(4):1430-1443. PubMed ID: 39187468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Hu Z; Medeiros LJ; Wang W; Chen Z; Tang G; Hodjat P; Yang S; Fang L; Li Y; Verstovsek S; Hu S
    Mod Pathol; 2017 Jul; 30(7):940-951. PubMed ID: 28338652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.
    Liu H; Wang SA; Schlette EJ; Xu J; Jorgensen JL; Cameron Yin C; Li S; Jeffrey Medeiros L; Tang G
    Ann Hematol; 2018 Oct; 97(10):1775-1783. PubMed ID: 29872884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of rare subtypes of acute myeloid leukaemia and related neoplasms.
    George TI; Bajel A
    Pathology; 2021 Apr; 53(3):312-327. PubMed ID: 33676766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations.
    Tang Z; Tang G; Hu S; Patel KP; Yin CC; Wang W; Lin P; Toruner GA; Ok CY; Gu J; Lu X; Khoury JD; Medeiros LJ
    Cancer Genet; 2019 Apr; 233-234():21-31. PubMed ID: 31109591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24).
    Lennon PA; Abruzzo LV; Medeiros LJ; Cromwell C; Zhang X; Yin CC; Kornblau SM; Konopieva M; Lin P
    Cancer Genet Cytogenet; 2007 Aug; 177(1):37-42. PubMed ID: 17693189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of both double minute of C-MYC and BCL-2 rearrangement containing large B-cell lymphoma with subsequent unfortunate development of therapy-related acute myeloid leukemia with t(3;3)(q26.2;q21).
    Nguyen JC; Kubik MJ; Broome HE; Curtin PT; Dell'Aquila ML; Wang HY
    Pathol Res Pract; 2015 Nov; 211(11):883-91. PubMed ID: 26300063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
    Wang HY; Rashidi HH
    Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.